Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients.

van Dijk EH, Duits DE, Versluis M, Luyten GP, Bergen AA, Kapiteijn EW, de Lange MJ, Boon CJ, van der Velden PA.

Medicine (Baltimore). 2016 May;95(18):e3457. doi: 10.1097/MD.0000000000003457.

2.

Separation of outer retinal layers secondary to selumetinib.

Avery RA, Trimboli-Heidler C, Kilburn LB.

J AAPOS. 2016 Jun;20(3):268-71. doi: 10.1016/j.jaapos.2016.01.012. Epub 2016 Apr 21.

PMID:
27108842
3.

Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.

Moore EC, Cash HA, Caruso AM, Uppaluri R, Hodge JW, Van Waes C, Allen CT.

Cancer Immunol Res. 2016 Jul;4(7):611-20. doi: 10.1158/2326-6066.CIR-15-0252. Epub 2016 Apr 13.

PMID:
27076449
4.

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.

Bournet B, Muscari F, Buscail C, Assenat E, Barthet M, Hammel P, Selves J, Guimbaud R, Cordelier P, Buscail L.

Clin Transl Gastroenterol. 2016 Mar 24;7:e157. doi: 10.1038/ctg.2016.18.

5.

Targeting mutant NRAS signaling pathways in melanoma.

Vu HL, Aplin AE.

Pharmacol Res. 2016 May;107:111-6. doi: 10.1016/j.phrs.2016.03.007. Epub 2016 Mar 15. Review.

PMID:
26987942
6.

mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer.

Cash H, Shah S, Moore E, Caruso A, Uppaluri R, Van Waes C, Allen C.

Oncotarget. 2015 Nov 3;6(34):36400-17. doi: 10.18632/oncotarget.5063.

7.

Recent advances in the treatment of melanoma with BRAF and MEK inhibitors.

Muñoz-Couselo E, García JS, Pérez-García JM, Cebrián VO, Castán JC.

Ann Transl Med. 2015 Sep;3(15):207. doi: 10.3978/j.issn.2305-5839.2015.05.13. Review.

8.

PIMASERTIB AND SEROUS RETINAL DETACHMENTS.

AlAli A, Bushehri A, Park JC, Krema H, Lam WC.

Retin Cases Brief Rep. 2016 Spring;10(2):191-6. doi: 10.1097/ICB.0000000000000228.

9.

Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.

Chua KN, Kong LR, Sim WJ, Ng HC, Ong WR, Thiery JP, Huynh H, Goh BC.

Oncotarget. 2015 Oct 6;6(30):29991-30005. doi: 10.18632/oncotarget.5031.

10.

Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.

Monsma DJ, Cherba DM, Eugster EE, Dylewski DL, Davidson PT, Peterson CA, Borgman AS, Winn ME, Dykema KJ, Webb CP, MacKeigan JP, Duesbery NS, Nickoloff BJ, Monks NR.

Am J Cancer Res. 2015 Mar 15;5(4):1507-18. eCollection 2015.

11.

Computational and Biochemical Discovery of RSK2 as a Novel Target for Epigallocatechin Gallate (EGCG).

Chen H, Yao K, Chang X, Shim JH, Kim HG, Malakhova M, Kim DJ, Bode AM, Dong Z.

PLoS One. 2015 Jun 17;10(6):e0130049. doi: 10.1371/journal.pone.0130049. eCollection 2015.

12.

MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.

Duncan KE, Chang LY, Patronas M.

Eye (Lond). 2015 Aug;29(8):1003-12. doi: 10.1038/eye.2015.82. Epub 2015 Jun 5. Review.

13.

Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts.

Andersen NJ, Boguslawski EB, Kuk CY, Chambers CM, Duesbery NS.

Int J Oncol. 2015 Jul;47(1):71-80. doi: 10.3892/ijo.2015.2989. Epub 2015 May 6.

14.

Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.

Jousma E, Rizvi TA, Wu J, Janhofer D, Dombi E, Dunn RS, Kim MO, Masters AR, Jones DR, Cripe TP, Ratner N.

Pediatr Blood Cancer. 2015 Oct;62(10):1709-16. doi: 10.1002/pbc.25546. Epub 2015 Apr 22.

PMID:
25907661
15.

Disentangling the Complexity of HGF Signaling by Combining Qualitative and Quantitative Modeling.

D'Alessandro LA, Samaga R, Maiwald T, Rho SH, Bonefas S, Raue A, Iwamoto N, Kienast A, Waldow K, Meyer R, Schilling M, Timmer J, Klamt S, Klingmüller U.

PLoS Comput Biol. 2015 Apr 23;11(4):e1004192. doi: 10.1371/journal.pcbi.1004192. eCollection 2015 Apr.

16.

MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.

Bian Y, Han J, Kannabiran V, Mohan S, Cheng H, Friedman J, Zhang L, VanWaes C, Chen Z.

Int J Biol Sci. 2015 Feb 23;11(4):411-22. doi: 10.7150/ijbs.10745. eCollection 2015.

17.

Treatment of NRAS-mutant melanoma.

Johnson DB, Puzanov I.

Curr Treat Options Oncol. 2015 Apr;16(4):15. doi: 10.1007/s11864-015-0330-z. Review.

18.

Targeting drivers of melanoma with synthetic small molecules and phytochemicals.

Strickland LR, Pal HC, Elmets CA, Afaq F.

Cancer Lett. 2015 Apr 1;359(1):20-35. doi: 10.1016/j.canlet.2015.01.016. Epub 2015 Jan 15. Review.

19.

A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.

El Meskini R, Iacovelli AJ, Kulaga A, Gumprecht M, Martin PL, Baran M, Householder DB, Van Dyke T, Weaver Ohler Z.

Dis Model Mech. 2015 Jan;8(1):45-56. doi: 10.1242/dmm.018168. Epub 2014 Nov 27.

20.

Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.

Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S.

PLoS One. 2014 Nov 17;9(11):e113037. doi: 10.1371/journal.pone.0113037. eCollection 2014.

Items per page

Supplemental Content

Write to the Help Desk